# EDGAR Filing Document

**Accession Number:** 0001817229
**File Stem:** 0001193125-25-193600
**Filing Date:** 2025-9
**Character Count:** 35586
**Document Hash:** 83457ab0a7e2fa445fc54c05d4d86d98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-193600.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001193125-25-193600

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 53

**CONFORMED PERIOD OF REPORT**: 20250902

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250902

**DATE AS OF CHANGE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39979
- **FILM NUMBER:** 251283543

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMBRIDGEPARK DRIVE
- **STREET 2:** SUITE 101
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMBRIDGEPARK DRIVE
- **STREET 2:** SUITE 101
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): September 2, 2025

## Vor Biopharma Inc.

#### (Exact name of registrant as specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39979** | **81-1591163** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **500 Boylston Street** |  |
| **Suite 1350** |  |
| **Boston, Massachusetts** | **02116** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (617) 655-6580

#### P.O. Box 380121

#### Cambridge, Massachusetts 02238

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.0001 par value per share | VOR | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.**  |

---

Vor Biopharma Inc. (the "Company") from time to time presents and/or distributes to the investment community presentations related to its business. A copy of its most recent presentation is available on the Company's website and is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| 99.1 | [Corporate Presentation, dated September 2025.](d80161dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 2, 2025 | **Vor Biopharma Inc.** | **Vor Biopharma Inc.** |
|  | By: | /s/ Jean-Paul Kress |
|  | Name: | Jean-Paul Kress |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

![Slide 1](g80161ex99_1s1g1.jpg)

Global Science. One Purpose. Corporate Presentation September 2025 Exhibit 99.1

------

![Slide 2](g80161ex99_1s2g1.jpg)

Forward Looking Statement This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The words "aim," "anticipate," "believe," "can," "could," "design," "enable" "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "project," "should," "target," "towards," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Presentation include those regarding Vor Bio's plans for development and commercialization of telitacicept, the potential of telitacicept in various indications including generalized myasthenia gravis (gMG) and primary Sjögren's disease, the potential of telitacicept to be a best- and first-in-class BAFF/APRIL inhibitor globally in gMG, the potential best-in-disease profile of telitacicept in primary Sjögren's disease, the availability of data from clinical trials including those conducted by third parties, the expected safety profile of telitacicept, the market opportunities for telitacicept, the addressable patient populations in the indications Vor Bio intends to treat, telitacicept's therapeutic potential, Vor Bio's cash runway and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, completion of, and availability and timing of results from, preclinical studies and clinical trials; whether preclinical data or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the uncertainty of regulatory approvals to conduct trials or to market products; Vor Bio's reliance on third parties over which it may not always have full control; and the availability of funding sufficient for Vor Bio's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this Presentation speak only as of the date of this Presentation, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and Vor Bio's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this Presentation, the Company has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. In addition, there can be no guarantee as to the accuracy or reliability of any assumptions or limitations that may be included in such third-party information. While the Company believes its own internal research is reliable, such research has not been verified by any independent source. All brand names or trademarks appearing in this Presentation are the property of their respective owners.

------

![Slide 3](g80161ex99_1s3g1.jpg)

China Is Now the Epicenter of Drug Innovation 50%+ of new global molecules originate in China Out-licensing deals are surging ($58B+ in 2025) ICH, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use; Source: Bloomberg and Bernstein analysis; 1. Bloomberg, SMMT:NASDAQ 2. BioNTech and BMS release The Next Breakthrough Wave Is Coming From China Validation in China is Globally Credible Strong data across biotech sector Faster, larger trials with strong signals NMPA aligned with ICH standards Western Deals Unlock Massive Value Summit/Akeso1: $17B+ market cap gain Biotheus – BioNTech – BMS2: $1B to $11B+ Proven model: China assets scale globally

------

![Slide 4](g80161ex99_1s4g1.jpg)

01 The Medicine Meets the Moment 02 03 04 Telitacicept Dual BAFF/APRIL Inhibitor Optimal approach for B cell driven autoimmune diseases Addresses upstream and downstream signaling Myasthenia Gravis The Beachhead Indication Best-in-disease foundation from China Phase 3 clinical study Market shifting from symptom control to disease modification Significant Expansion Opportunities Blockbuster potential in multiple autoimmune indications Sjögren's Disease: The next multi-billion-dollar opportunity World Class Management Team Domain experts in autoimmune diseases, clinical development, and commercialization

------

![Slide 5](g80161ex99_1s5g1.jpg)

Telitacicept Leads the BAFF/APRIL Field with Broad Approval Momentum Strong cash position of $190M\* with runway into 1Q27 covers critical milestones Indications Preclinical Phase 1 Phase 2 Phase 3 Marketing Approval Milestones Systemic Lupus Erythematosus (SLE) Rheumatoid Arthritis (RA) Myasthenia Gravis (MG) OLE 48-wk Data – AANEM (10.29.25) Topline Global Data 1H27 IgA Nephropathy (IgAN) Dataset at Upcoming Medical Meeting Primary Sjögren's Disease (pSD) Dataset at Upcoming Medical Meeting FDA Cleared Global Phase 3 Neuromyelitis Optica Spectrum Disorder (NMSOD) Lupus Nephritis (LN) Membranous Nephritis (MN) and Other Indications China Marketed China Marketed China Marketed BLA Submitted BLA Submitted Phase 3 Phase 2 Phase 3 Phase 3 Ready Phase 2 Vor – Global Trial RemeGen – China Trial Primary Endpoint Achieved \*cash and cash equivalents as of June 30, 2025

------

![Slide 6](g80161ex99_1s6g1.jpg)

Disease Modification Through Upstream and Downstream Control Ab, antibody Dual BAFF/APRIL blockade stops B cell survival and plasma cell antibody production Drives B cell development and survival Promotes proliferation of mature B cells BAFF Upstream BAFF APRIL Telitacicept TACI-Fc fusion protein: dual inhibition of BAFF/APRIL B cell differentiation Isotype-switching B cell survival maturation Plasma cell survival Anti-inflammation B-cell function Sustains long-lived plasma cells in bone marrow Supports pathogenic Ab production Drives Ig isotype class switching APRIL Upstream + Downstream Telitacicept Dual blockade of BAFF/APRIL Normalization of B cell function Cuts off plasma cell persistence + Ab production Restores immune balance Upstream + Downstream doi.org/10.3390/cancers12041045

------

![Slide 7](g80161ex99_1s7g1.jpg)

Commercial Approvals †Conditional Approval, Full Approval in 2023; \*Accelerated Approval in China; Est., estimated Unprecedented Efficacy in China Across Autoimmune Diseases BLA Submissions Best-In-Disease in China 3 2 3 2021 - Systemic Lupus Erythematosus (SLE)† 2024 - Rheumatoid Arthritis (RA) 2025 - Myasthenia Gravis (MG) Est. 2026 - Primary Sjögrens Disease (pSD) Est. 2026 - IgA Nephropathy (IgAN)\* Validated Commercial Therapy in China Across Diverse Autoimmune Diseases Poised to Further Expand Telitacicept Footprint in Large, Underserved Diseases in China Unique Dual BAFF/APRIL Inhibition Drives Superior Clinical Benefit Systemic Lupus Erythematosus Myasthenia Gravis Primary Sjögrens Disease

------

![Slide 8](g80161ex99_1s8g1.jpg)

\*From pooled safety analysis across all telitacicept trials. AEs, adverse events; SAEs, serious adverse events. Favorable Safety At Scale Favorable and Predictable Safety Profile Observed Among ~1,800\* Patients Studied in Clinical Trials No Burdensome Vaccination Requirements No Signature B Cell Depletion Associated SAEs Mild to Moderate AEs Placebo (n=527) Telitacicept (n=1211) Blood IgM decreased 2 6 Blood IgG decreased 1 5 Cough 3 5 Diarrhea 5 5 Urinary tract infection 9 10 Injection site reaction 2 17 Upper respiratory tract infection 30 35 >70,000 Patients Treated Commercially in China Frequency (%) of safety events reported in clinical trials

------

![Slide 9](g80161ex99_1s9g1.jpg)

A Pipeline of Autoantibody-Driven Diseases & Blockbuster Opportunities ANCA-AAV, ANCA-associated Vasculitis; ITP, Immune Thrombocytopenic Purpura; CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy; NMOSD, Neuromyelitis Optica Spectrum Disorder; IgG4-RD, IgG4-related disease. Telitacicept can potentially address more than 1 million patients1 in the US alone CIDP 30,000 Sjögren's Disease 290,000 ANCA-AAV 140,000 SLE 240,000 Myasthenia Gravis 90,000 NMOSD 25,000 ITP 65,000 Bullous Pemphigoid 40,000 Membraneous Nephropathy 70,000 IgG4-RD 20,000 Lupus Nephritis 105,000 1. Vor metanalysis and estimates

------

![Slide 10](g80161ex99_1s10g1.jpg)

Myasthenia Gravis Moving Beyond IgG Therapies

------

![Slide 11](g80161ex99_1s11g1.jpg)

A Large and Growing Global Opportunity in Myasthenia Gravis ~260,000 diagnosed MG patients across key markets1 Significant Burden A large, diagnosed patient population across key markets establishes a substantial initial opportunity Favorable Growth Drivers Prevalence is growing due to increased awareness, improved diagnostics, and an aging population ~90k US prevalence ~140k EU prevalence ~29k Japan prevalence ~220k China prevalence MG, myasthenia gravis 1. Vor metanalysis and estimates; excludes Chinese market

------

![Slide 12](g80161ex99_1s12g1.jpg)

MG Market Rapidly Expanding But Lacks Disease-Modifying Treatments MG, myasthenia gravis; gMG: generalized myasthenia gravis; 1. EvaluatePharma and Global Data sales and consensus High growth market with underserved patient segments gMG US Biologic Sales ~90,000 Diagnosed MG patients in the US 60% Potential expansion of branded medicines in eligible gMG patients 62% CAGR increase since 2018 ~$3.7B1 ~$10.7B1 Projected Market Size (2030)

------

![Slide 13](g80161ex99_1s13g1.jpg)

Biologic use rising (~35% of gMG patients1) with choices driven by efficacy, convenience, phenotype, and coverage FcRn inhibitors dominate but ~20-50% of patients experience insufficient treatment responses2 Complement inhibitors limited by safety, black box warning, and vaccination requirements3 B cell depleting and cell therapies face challenges with efficacy, safety, and logistical limits despite disease-modifying potential4 Current Myasthenia Gravis Therapies Target Symptoms, Not Disease AChEI, acetylcholinesterase inhibitors; AChR, acetylcholine receptor; FcRn, neonatal Fc receptor; IVIG, intravenous immune globulin; MuSK, muscle-specific tyrosine kinase; PLEX, plasma exchange; RTX, rituximab; ISx, immunosuppressants. Even with the availability of biologics, unmet need for new therapies remain 1. Wedbush Neurologist Surveys 2. doi: 10.1136/jnnp-2024-334404 3. ULTOMIRIS, SOLIRIS label 4. doi: 10.1007/s40259-020-00443-w AChR+ MG AChEi Steroids ISx MuSK+ MG Steroids ± RTX RTX FcRn Antagonists C5 Inhibitors, IVIG, PLEX IVIG, PLEX

------

![Slide 14](g80161ex99_1s14g1.jpg)

Phase 3 Trial in Generalized Myasthenia Gravis Completed in China MG-ADL; Myasthenia Gravis Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; QW, per week. ClinicalTrials.gov. NCT05737160. Updated May 5, 2025. Accessed August 19, 2025. https://clinicaltrials.gov/study/NCT05737160 Best-in-disease profile in China; randomized, double-blind, placebo-controlled study gMG R 1:1 114 Adults With gMG Double-Blind Treatment Period (24 Weeks) Open-Label Extension Period (24 Weeks) Telitacicept (240mg QW) Placebo Telitacicept (240mg QW) Primary Endpoint Change from baseline in MG-ADL at 24 weeks Secondary Endpoints Change from baseline in MG-ADL at 12, 36, and 48 weeks Change from baseline in QMG at 12, 24, 36, and 48 weeks Number of patients with ≥3 point decrease in MG-ADL, ≥5 point decrease in QMG at 24 and 48 weeks RemeGen-sponsored trial

------

![Slide 15](g80161ex99_1s15g1.jpg)

Well Balanced Baseline Characteristics Consistent with recent global Phase 3 populations AE, adverse event; AChR, acetylcholine receptor; EP, efficacy population; MG-ADL, Myasthenia Gravis-Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; MuSK, muscle-specific tyrosine kinase; QMG, Quantitative Myasthenia Gravis; SD, standard deviation; RS, randomized set; SS, safety set Telitacicept (N=57) Placebo (N=57) Age (yr), mean ± SD 49.1 ± 14.69 49.6 ± 15.03 Sex Male, n (%) 30 (52.6) 21 (36.8) Female, n (%) 27 (47.4) 36 (63.2) Disease duration (month), mean± SD 83.09 ± 84.507 76.05 ± 87.817 MGFA classification Class IIa, n (%) 3 (5.3) 12 (21.1) Class IIb, n (%) 14 (24.6) 9 (15.8) Class IIIa, n (%) 25 (43.9) 23 (40.4) Class IIIb, n (%) 11 (19.3) 12 (21.1) Class IVa, n (%) 4 (7.0) 1 (1.8) Baseline MG-ADL score, mean ± SD 10.0 ± 2.60 9.9 ± 2.62 Baseline QMG score, mean ± SD 17.9 ± 3.43 18.8 ± 3.65 Antibody-positive at screening AChR, n (%) 55 (96.5) 55 (96.5) MuSK, n (%) 2 (3.6) 2 (3.5) Standard-of-care therapy Anticholinesterase inhibitors, n (%) 53 (93.0) 52 (91.2) Steroids, n (%) 36 (63.2) 34 (59.6) Immunosuppressants, n (%) 34 (59.6) 34 (59.6) Screening (n=148) Randomized (n=114) Received Double-Blind Treatment (n=114) Telitacicept (n=57) Placebo (n=57) Completed Treatment (n=54) Completed Study (n=54) Completed Treatment (n=50) Completed Study (n=52) RS (n=57) EP (n=57) SS (n=57) RS (n=57) EP (n=57) SS (n=57) Discontinued Treatment (n=3) Discontinued Study (n=3) Discontinued Treatment (n=7) Discontinued Study (n=5) gMG RemeGen-sponsored trial

------

![Slide 16](g80161ex99_1s16g1.jpg)

MG-ADL Responders - Primary Endpoint Met MG-ADL, Myasthenia Gravis-Activities of Daily Living; MMRM, mixed models for repeated measures. Statistically significant and clinically meaningful improvement in activities of daily living -4.8 -5.74 -0.91 Change from Baseline in MG-ADL at Week 24 points Placebo-adjusted decrease in MG-ADL: The primary estimate was analyzed using MMRM. Intercurrent event was predefined, Missing data was imputed. gMG RemeGen-sponsored trial

------

![Slide 17](g80161ex99_1s17g1.jpg)

QMG Responders - Secondary Endpoint Met QMG, Quantitative Myasthenia Gravis; MMRM, mixed models for repeated measures. Statistically significant and clinically meaningful improvement in physician-assessed measure of muscle strength -6.4 -8.66 -2.27 Change from Baseline in QMG at Week 24 points Placebo-adjusted decrease in QMG: The data was analyzed using MMRM. Missing data was imputed, and as observed (AO) analysis was performed. gMG RemeGen-sponsored trial

------

![Slide 18](g80161ex99_1s18g1.jpg)

Telitacicept: Potential Best-In-Disease Efficacy Globally Statistically significant and clinically meaningful improvement in MG-ADL score -4.8 FcRn Inhibitors Complement Inhibitors Anti-CD19 mAb PBO-adjusted LSM MG-ADL Change from Baseline gMG RemeGen-sponsored trial MG-ADL, Myasthenia Gravis-Activities of Daily Living; MMRM, mixed models for repeated measures. Based on historical clinical data; not a head-to-head trial Efgartigimod - ADAPT; Nipocalimab - Vivacity-MG3; Rozanolixizumab – MycarinG; Ravulizumab – CHAMPION-MG; Eculizumab – REGAIN; Zilucoplan – RAISE; Inebilizumab - MINT

------

![Slide 19](g80161ex99_1s19g1.jpg)

Telitacicept Significantly Improved MG-ADL and QMG Scores gMG †Missing data imputed as non-response. MG-ADL, Myasthenia Gravis - Activities of Daily Living; QMG, Quantitative Myasthenia Gravis. Mean Change in QMG Score† -8.66 -2.27 Mean Change in MG-ADL Score† -5.74 -0.91 Proportion of patients with a ≥3 point reduction in MG-ADL score from baseline over time 12.0% 98.1% Proportion of patients with a ≥5 point reduction in QMG score from baseline over time 16.0% 87.0% RemeGen-sponsored trial

------

![Slide 20](g80161ex99_1s20g1.jpg)

Telitacicept Provides Sustained Disease Modification While FcRn Inhibitors Require Repeat Cycles †Missing data imputed as non-response. MG-ADL, Myasthenia Gravis - Activities of Daily Living REMEGEN Phase 3 China Trial -5.74 -0.91 Argenx Phase 3 Adapt Trial Cross trial comparison = Mean Change in Total MG-ADL From Cycle 1 Baseline Over Time in AChR-Ab Positive Patients (mITT Analysis Set) Mean Change in MG-ADL Score† RemeGen-sponsored trial Based on historical clinical data; not a head-to-head trial

------

![Slide 21](g80161ex99_1s21g1.jpg)

Consistent Reduction in IgG, IgA, IgM, and B Cells gMG IgG -32.89% 0.69% IgA -59.57% 0.00% IGM -68.93% 0.53% B cell -24.37% 2.61% RemeGen-sponsored trial

------

![Slide 22](g80161ex99_1s22g1.jpg)

Favorable Safety Profile AE, adverse event; pSD, primary Sjogren's disease; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; IgAN, IgA nephropathy Consistent with data from clinical trials in SLE, RA, pSD, and IgAN, and post-marketing data gMG Telitacicept Placebo (n=57) (n=57) n (%) Events n (%) Events Infection-Associated AEs in >5% of patients Infections and infestations 26 (45.6) 46 34 (59.6) 50 Upper respiratory tract infection 12 (21.1) 17 20 (35.1) 24 Urinary tract infection 9 (15.8) 11 6 (10.5) 6 Pneumonia 1 (1.8) 1 6 (10.5) 6 Respiratory tract infection 1 (1.8) 1 2 (3.5) 2 Influenza 0 (0) 0 3 (5.3) 3 Number of Serious AEs 4 (7.0) 4 6 (10.5) 7 Pneumonia 1 (1.8) 1 4 (7.0) 4 COVID-19 pneumonia 1 (1.8) 1 0 (0) 0 Influenza 0 (0) 0 1 (1.8) 1 Upper respiratory tract infection 0 (0) 0 1 (1.8) 1 Open fracture 0 (0) 0 1 (1.8) 1 Pneumonitis 1 (1.8) 1 0 (0) 0 Accidental death 1 (1.8) 1 0 (0) 0 RemeGen-sponsored trial

------

![Slide 23](g80161ex99_1s23g1.jpg)

Telitacicept Targets What Matters and Preserves What Protects MoA, mechanism of action; MG-ADL, myasthenia gravis-activities of daily living; QMG, quantitative myasthenia gravis; PBO, placebo A balanced IgG and B cell reduction allows for superior outcomes MoA TACI-Fc Anti-FcRn Anti-CD19 IgG Reduction 25-35% 60-65% N/A CD19+ B cell reduction 20-40% NA 100% ΔMG-ADL vs. PBO -4.8 -2.8 -1.9 ΔQMG vs. PBO -6.4 -5.2 -2.5 Data readout Week 24 Week 4 Week 24 Tai' Ai泰爱® Telitacicept Based on historical clinical data; not a head-to-head trial 1. Argenx Phase 3 ADAPT Trial 2. Amgen Phase 3 MINT Trial gMG RemeGen-sponsored trial

------

![Slide 24](g80161ex99_1s24g1.jpg)

Global Phase 3 in Generalized Myasthenia Gravis MG-ADL, Myasthenia Gravis-Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; QW, per week. \*Estimated. †For patients who discontinue treatment before the open-label extension (OLE) period, end of treatment (EOT) and end of study (EOS) time points are at 24 and 32 weeks respectively. For those continuing with the OLE, EOT and EOS time points are at 72 and 80 weeks respectively. ClinicalTrials.gov. NCT05737160. Updated May 5, 2025. Accessed August 19, 2025. https://clinicaltrials.gov/study/NCT05737160 Potential best- and first-in-class BAFF/APRIL inhibitor; randomized, double-blind, placebo-controlled study Double Blind Treatment Period (24 Weeks) Open-Label Extension Period (48 Weeks) Telitacicept (240mg QW) Placebo Telitacicept (240mg QW) R 1:1 Primary Endpoint Change from baseline in MG-related ADL at week 24 Secondary Endpoints Change from baseline in QMG and MG-QOL15r at week 24 Number of patients with a ≥2 point decrease in MG-ADL at week 24 Number of patients with ≥3 point decrease in QMG at week 24 8-week follow-up† ~180\* Adults With gMG gMG

------

![Slide 25](g80161ex99_1s25g1.jpg)

Sjögren's Disease Moving Beyond Symptom Management

------

![Slide 26](g80161ex99_1s26g1.jpg)

Sjögren's: A Large, Vastly Underserved Autoimmune Disease DMARDs, disease-modifying anti-rheumatic drugs; ESSDAI, EULAR Sjögren's syndrome disease activity index Targeting ~100, 0001 addressable patient US opportunity with a potential best-in-disease profile Symptom-Directed Local/topical therapies for dryness Mild-to-Moderate (No Major Organ Involvement) DMARDs (hydroxychloroquine, methotrexate) Moderate Disease (ESSDAI ≥5, Non–Life Threatening) Immunosuppressants (Methotrexate, azathioprine, or cyclosporine) Severe Disease (Major Organ Involvement) High potency immunosuppressants, biologics Interstitial pneumonia Secondary Raynaud phenomenon Fatigue, difficulty concentrating Difficult swallowing, dry mouth, swollen glands Peripheral neuropathy Nephritis Cholangitis Small vessel vasculitis, purpura Polyarthritis Dry eyes 1 2 3 4 1. Vor metanalysis and estimates

------

![Slide 27](g80161ex99_1s27g1.jpg)

Sjögren's: One of the Most Common Systemic Autoimmune Diseases Globally ~870,000 diagnosed Sjögren's patients across key markets1 Favorable Growth Drivers Rising diagnosis rates from better awareness and testing Underpenetrated Market No approved disease-modifying systemic therapies Patients managed with symptomatic treatments ~290k US prevalence ~450k EU prevalence ~130k Japan prevalence ~1.2M China prevalence 1. Vor metanalysis and estimates; excludes Chinese market

------

![Slide 28](g80161ex99_1s28g1.jpg)

Phase 2 Trial in Primary Sjögren's Disease Completed in China ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; MFI, multidimensional fatigue inventory; MFI-20, multidimensional fatigue inventory; PGA, physician's global assessment; PaGA, patient's global assessment; SF-36, 36-item short-form; pSD, primary Sjögren's disease; QW, per week. Potential best-in-disease profile in China; randomized, double-blind, placebo-controlled study Primary Endpoint Change from baseline in ESSDAI at 24 weeks Secondary Endpoints Change from baseline in ESSDAI at 12 weeks Changes from baseline in ESSPRI, PGA, PaGA, SF-36 and MFI-20 at 12 and 24 weeks Double-Blind Treatment Period (24 Weeks) Telitacicept (240mg QW) Placebo Telitacicept (160mg QW) R 1:1:1 42 Adults With pSD pSD RemeGen-sponsored trial

------

![Slide 29](g80161ex99_1s29g1.jpg)

Well Balanced Baseline Characteristics ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; MFI, multidimensional fatigue inventory; MFI-20, multidimensional fatigue inventory; FAS, full analysis set; PPS, per-protocol set; SS, safety set; SD, standard deviation; \*Efficacy analyses of the ESSDAI change from baseline were based on the FAS and PPS. Other efficacy analyses were only performed based on the FAS Placebo (N=57) Telitacicept 160mg (N=57) Telitacicept 240mg (N=57) Female, n(%) 13 (92.9%) 13 (92.9%) 14 (100.0%) Age (years), mean (SD) 48.7 (13.5) 47.4 (12.4) 52.1 (11.8) BMI (kg/m2), mean (SD) 23.2 (2.4) 21.9 (2.3) 22.9 (2.6) Disease duration (month), mean (SD) 31.8 (51.1) 39.1 (68.2) 32.1 (48.8) ESSDAI, mean (SD) 9.9 (7.0) 7.3 (2.6) 8.9 (4.7) ESSPRI, mean (SD) 5.2 (1.8) 4.8 (2.2) 5.1 (2.3) MFI-20, mean (SD) 50.7 (16.1) 58.9 (10.1) 59.6 (16.6) Unstimulated salivary flow rate (g/min), mean (SD) 0.03 (0.05) 0.09 (0.10) 0.08 (0.10) Schirmer test (left eye, mm), mean (SD) 4.1 (3.4) 4.2 (2.2) 3.5 (4.0) Schirmer test (right eye, mm), mean (SD) 3.4 (2.5) 4.1 (2.9) 4.6 (4.5) IgG (g/L), mean (SD) 16.3 (4.6) 19.6 (6.1) 15.9 (4.4) IgA (g/L), mean (SD) 3.5 (1.6) 3.0 (1.2) 3.5 (1.5) IgM (g/L), mean (SD) 1.3 (0.7) 1.2 (0.4) 1.0 (0.4) CD19+ B cell (/ul) mean (SD) 193.7 (112.5) 157.8 (83.2) 189.0 (106.5) Baseline medication use, n(%) Hydroxychloroquine sulfate 7 (50.0%) 8 (57.1%) 7 (50.0%) Screening (n=57) Randomized (n=42) Received Double-Blind Treatment (n=42) Placebo (n=14) Telitacicept 240mg (n=14) Completed Study (n=10) Completed Study (n=8) FAS (n=14) PPS\* (n=10) SS (n=14) FAS (n=14) PPS\* (n=8) SS (n=14) Withdrawn (n=4) pSS Deterioration (n=1) Withdrawal By Subject (n=3) Telitacicept 160mg (n=14) Completed Study (n=12) FAS (n=14) PPS\* (n=12) SS (n=14) Withdrawn (n=2) Adverse Event (n=1) Withdrawal By Subject (n=1) Withdrawn (n=6) Adverse Event (n=3) Withdrawal By Subject (n=2) Lack of Efficacy (n=1) pSD RemeGen-sponsored trial

------

![Slide 30](g80161ex99_1s30g1.jpg)

-3.8 +0.5 ESSDAI Responders - Primary Endpoint Met ESSDAI, EULAR Sjögren's syndrome disease activity index Statistically significant and clinically meaningful improvement in ESSDAI at week 24 -4.3 Change from Baseline in ESSDAI at Week 24 points Placebo-adjusted decrease in ESSDAI: pSD -2.3 Xu D, et al. Rheumatology. 2024;63:698-705. RemeGen-sponsored trial

------

![Slide 31](g80161ex99_1s31g1.jpg)

Telitacicept: Potential Best-In-Disease Efficacy Globally Statistically significant and clinically meaningful improvement in activities of daily living -4.3 FcRn Inhibitors Anti-BAFF-R mAb CD40L Antagonist PBO-adjusted LSM MG-ADL Change from Baseline pSD Efgartigimod - RHO; Nipocalimab - Bowman 2022, Lancet; Ianalumab - St. Clair 2024, Nature; Dazodalibep - Xu 2024 Rheumatology ESSDAI, EULAR Sjögren's syndrome disease activity index; mAb, monoclonal antibody n=54 n=23 n=47 n=36 n=14 RemeGen-sponsored trial Based on historical clinical data; not a head-to-head trial

------

![Slide 32](g80161ex99_1s32g1.jpg)

Consistent Reduction in IgG, IgA, IgM, and B Cells pSD IgG IgA IGM B cell RemeGen-sponsored trial

------

![Slide 33](g80161ex99_1s33g1.jpg)

Favorable Safety Profile † AEs occurring in ≥ 2 subjects in any treatment group were listed. TEAE, treatment-emergent adverse event. Consistent with data from clinical trials in SLE, RA, gMG, and IgAN, and post-marketing data Placebo (N=14) Telitacicept 160 mg (N=14) Telitacicept 240 mg (N=14) TEAE, n(%) 13(92.9%) 12(85.7%) 14(100.0%) Drug-related TEAEs, n(%) 9(64.3%) 9(64.3%) 14(100.0%) TEAE leading to discontinuation, n(%) 1(7.1%) 1(7.1%) 3(21.4%) SAE, n(%) 1(7.1%) 0(0) 0(0) Drug-related SAEs, n(%) 1(7.1%) 0(0) 0(0) Death, n(%) 0(0) 0(0) 0(0) Infections and infestations† (SOC), n(%) 8(57.1%) 9(64.3%) 5(35.7%) Upper respiratory tract infections, n(%) 7(50.0%) 6(42.9%) 4(28.6%) Urinary tract infection, n(%) 1(7.1%) 2(14.3%) 0(0) Nasopharyngitis, n(%) 2(14.3%) 0(0) 0(0) pSD RemeGen-sponsored trial AE, adverse event; pSD, primary Sjogren's disease; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; IgAN, IgA nephropathy

------

![Slide 34](g80161ex99_1s34g1.jpg)

Phase 3 Trial in Primary Sjögren's Disease Completed in China Potential best-in-disease profile in China; randomized, double-blind, placebo-controlled study pSD \*Estimated. ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; MFI, multidimensional fatigue inventory; MFI-20, multidimensional fatigue inventory; PGA, physician's global assessment; PaGA, patient's global assessment; SF-36, 36-item short-form; pSD, primary Sjögren's disease; QW, per week. 380\* Adults With pSD Primary Endpoint Change from baseline in ESSDAI at 24 weeks Secondary Endpoints Change from baseline in ESSDAI at 12 weeks Changes from baseline in ESSPRI, PGA, PaGA, SF-36 and MFI-20 at 12 and 24 weeks Double-Blind Treatment Period (24 Weeks) R 1:1:1 Telitacicept (80mg QW) Telitacicept (160mg QW) Double-Blind Treatment Period (24 Weeks) Telitacicept (80mg QW) Telitacicept (160mg QW) Placebo R 1:1 RemeGen-sponsored trial

------

![Slide 35](g80161ex99_1s35g1.jpg)

2025 90k US patients Myasthenia Gravis 2026 380k US patients Myasthenia Gravis Primary Sjögren's Disease 2027+ 1M+ US patients Myasthenia Gravis Sjögren's Disease Systemic Lupus Erythematosus ANCA-associated Vasculitis Membraneous Nephropathy Immune Thrombocytopenic Purpura Bullous Pemphigoid Chronic Inflammatory Demyelinating Polyradiculoneuropathy Neuromyelitis Optica Spectrum Disorder IgG4-Related Disease Significant Near-Term Expansion Opportunities 1. Vor metanalysis and estimates

------

![Slide 36](g80161ex99_1s36g1.jpg)

gMG pSD Validating Biomarker Data Established Dose China Phase 3 Completed China Regulatory Status Global Phase 3 Enrolling Phase 3 Ready Launched BLA to be Submitted A Validated Therapy Poised For Rapid Global Expansion

------

![Slide 37](g80161ex99_1s37g1.jpg)

Three Phase 3 China Readouts in Large Indications Before Year-End \*Timing of readouts based on Remegen public statements; PBO, placebo; OLE, open-label extension; MG, myasthenia Gravis Each positive readout\* strengthens the pathway to global commercialization Data: n=114, OLE 48-weeks Myasthenia Gravis Sjögren's Disease IgAN Data: n=380, double-blind 48-weeks Data: n=318, double-blind 39-weeks Long-term efficacy could further strengthen market position High potential to disrupt global/US markets Large strategic growth opportunity with unmet medical need Highly differentiated MOA and efficacy profile in Phase 2 Validation of Chinese data vs global competitor studies Not a prioritized indication for Vor Readthrough Readthrough Readthrough China Phase 3 Trial China Phase 3 Trial China Phase 3 Trial PRIMARY ENDPOINT ACHIEVED PRIMARY ENDPOINT ACHIEVED PRIMARY ENDPOINT ACHIEVED

------

![Slide 38](g80161ex99_1s38g1.jpg)

Telitacicept Leads the BAFF/APRIL Field with Broad Approval Momentum Strong cash position of $190M\* with runway into 1Q27 covers critical milestones Indications Preclinical Phase 1 Phase 2 Phase 3 Marketing Approval Milestones Systemic Lupus Erythematosus (SLE) Rheumatoid Arthritis (RA) Myasthenia Gravis (MG) OLE 48-wk Data – AANEM (10.29.25) Topline Global Data 1H27 IgA Nephropathy (IgAN) Dataset at Upcoming Medical Meeting Primary Sjögren's Disease (pSD) Dataset at Upcoming Medical Meeting FDA Cleared Global Phase 3 Neuromyelitis Optica Spectrum Disorder (NMSOD) Lupus Nephritis (LN) Membranous Nephritis (MN) and Other Indications China Marketed China Marketed China Marketed BLA Submitted BLA Submitted Phase 3 Phase 2 Phase 3 Phase 3 Ready Phase 2 Vor – Global Trial RemeGen – China Trial Primary Endpoint Achieved \*cash and cash equivalents as of June 30, 2025

------

![Slide 39](g80161ex99_1s39g1.jpg)

Thank You. Investors@vorbio.com